Search Results - "Malan, DR"

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial by Parrino, Janie, Popmihajlov, Zoran, Annunziato, Paula W, Fein, L, Singh, M, Morrissey, O, Kuehr, T, Duck, L, De Prijck, B, Serrano, SV, Camargo, JFC, Radinov, A, Minchev, V, Grimard, D, Weiss, K, Diaz-Mitoma, FJ, Torres Ulloa, R, Fardella, P, Gonzalez, P, Gonzalez, ME, Rojas, CA, Paulson, G, Ontaneda, M, Laine, F, Laurichesse, H, Duval, X, Cornely, OA, Zaiss, M, Verbeek, M, Georgoulias, V, Terpos, E, Umanzor, J, Bejarano, S, Gentile, G, Rambaldi, A, Marei, L, Abbadi, A, Kattan, J, Blacklock, H, Tiangco, BJ, Cabanillas, F, Ciuleanu, TE, Cainap, CI, Dvorkin, MV, Litvinov, IV, Goh, YT, Matejkova, M, Reckova, M, Yoon, SS, Duran Martinez, I, Chen, C-Y, Sriuranpong, V, Akan, H, Mullan, SR, Sivarajan, K, Marquez, F, Mullane, MR, Mazurczak, MA, Zenk, D, Robinson, MO, Naqvi, T, Ahmed, M, Badarinath, S, Kendall, SD, Chedid, S, Rafiyath, S, Buechler-Price, J, Sreenivasappa, S, Geller, R, Nieva, J, Wong, BMY, Ibrahim, EN, Oliff, IA, Guter, KA, Rao, SB, Columbie, A, Nualart, MT, Campos, LT, Sharma, S, Ortiz, T, Markowitz, AB, Koo, VS, Murray, C, Gurtler, JS, Ascensao, JL, Santander, JL, Garg, RJ, Lowry, P, Baker, J, Roeland, E, Payne, JE, Betts, RF, Sharp, SA, Congdon, J, Wos, EJ, Hutchins, M, Chowhan, NM, O'Rourke, TJ, Winkler, CF, Duic, JP

“…Patients who are immunocompromised because of malignancy have an increased risk of herpes zoster and herpes zoster-related complications. We aimed to…”
Get full text

Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients by MALAN, D. R, KRANTZ, Edrich, DAVID, Neal, WIRTZ, Victoria, HAMMOND, Janet, MCGRATH, Donnie

“…Atazanavir (ATV), the first once-daily protease inhibitor approved for the treatment of HIV-1 infection, is recommended for use in antiretroviral (ARV)…”
Get full text

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study by van Leth, F, Phanuphak, P, Ruxrungtham, K, Baraldi, E, Miller, S, Gazzard, B, Cahn, P, Lalloo, UG, van der Westhuizen, IP, Malan, DR, Johnson, MA, Santos, BR, Mulcahy, F, Wood, R, Levi, GC, Reboredo, G, Squires, K, Cassetti, I, Petit, D, Raffi, F, Katlama, C, Murphy, RL, Horban, A, Dam, JP, Hassink, E, van Leeuwen, R, Robinson, P, Wit, FW, Lange, JMA

“…The 2NN Study was a randomised comparison of the non-nucleoside reverse-transcriptase inhibitors (NNRTI) nevirapine and efavirenz. In this multicentre,…”
Get full text

96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients by Malan, D R Niel, Krantz, Edrich, David, Neal, Rong Yang, Mathew, Marina, Iloeje, Uchenna H, Jun Su, McGrath, Donnie

“…This study assesses virologic response, safety, tolerability, and changes in health-related quality of life (HRQoL) in antiretroviral (ARV)-naive patients…”
Get full text

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study by van Leth, F, Phanuphak, P, Ruxrungtham, K, Baraldi, E, Miller, S, Gazzard, B, Cahn, P, Lalloo, U G, van der Westhuizen, IP, Malan, DR, Johnson, MA, Santos, B R, Mulcahy, F, Lange, JMA

“…The 2NN Study was a randomised comparison of the non-nucleoside reverse-transcriptase inhibitors (NNRTI) nevirapine and efavirenz. In this multicentre,…”
Get full text